Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

38.00

Mkt cap

243B

Volume

134K

High

38.00

P/E Ratio

19.93

52-wk high

42.43

Low

37.44

Div yield

0.04

52-wk low

29.20

The U.S. may have reached a turning point in its fight against obesity, with new weight loss drugs like Ozempic and Wegovy contributing to a decline in obesity rates. Novo Nordisk, Eli Lilly, and Roche Holdings are key players in this pharmaceutical shift.

Portfolio Pulse from Benzinga Neuro

October 07, 2024 | 2:46 am

Roche Holdings AG is accelerating the development of its obesity drug CT-388, aiming for over $3 billion in sales. The company is also cutting drug development costs and time, with plans to launch 20 transformative medicines by 2030. Roche is expanding its portfolio with a $850 million acquisition from Regor Pharmaceuticals.

Portfolio Pulse from Vandana Singh

September 30, 2024 | 3:39 pm

Genentech, part of Roche Group, announced positive Phase III results for Gazyva in treating lupus nephritis, showing improved renal response and potential to delay kidney disease progression. The findings could offer a new treatment option for lupus patients.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 6:44 am

Roche's phase 3 CENTERSTONE study shows that Xofluza, an antiviral drug, significantly reduces the transmission of influenza viruses. The study met its primary endpoint, indicating a single dose can prevent household transmission. This adds to Xofluza's benefits, which is already approved for treating and preventing influenza. The study was partially funded by US federal agencies.

Portfolio Pulse from Vandana Singh

September 19, 2024 | 4:13 pm

Roche's Genentech has announced that its Phase III CENTERSTONE study of Xofluza shows a significant reduction in the transmission of influenza viruses. This is the first antiviral for respiratory viral illness to demonstrate such a benefit in a global Phase III study, potentially easing the burden on healthcare systems.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 6:03 am

Roche Holdings AG received FDA approval for two subcutaneous injections: Ocrevus Zunovo for multiple sclerosis and Tecentriq Hybreza for various cancers. These approvals offer faster administration times compared to traditional IV methods.

Portfolio Pulse from Vandana Singh

September 16, 2024 | 3:23 pm

Genentech, part of Roche Group, has received FDA approval for Ocrevus Zunovo, a twice-a-year subcutaneous injection for multiple sclerosis, offering a new treatment option for patients.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 5:24 pm

Roche's Genentech and Halozyme have received FDA approval for Tecentriq Hybreza, the first subcutaneous PD-(L)1 cancer immunotherapy. This new option offers faster treatment times and maintains the safety and efficacy of the intravenous version.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 7:15 am

Roche shares are experiencing a decline in trading following the release of weight loss data.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 7:52 pm

Roche's CT-996 Phase 1 trial for an obesity pill showed promising results, with the best-performing cohort achieving a 7.3% weight loss over four weeks, compared to a 1.2% loss in the placebo group. The placebo-adjusted average weight loss was 6.1% in one of the active cohorts.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 3:49 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.